TP53 and prostate carcinoma: In another study, treatment of LNCaP prostate cancer cells with 2-DG in combination with the AMPK activator metformin, resulted in activation of pro-death pathways in vitro inducing p53-dependent apoptosis via the energy sensor pathway AMPK [37].